The Fact About BCAT-IN-4 That No One Is Suggesting
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage numerous intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Major demo objectives had been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis suf